Cargando…
Axitinib in sequential therapy in metastatic renal cell carcinoma
Efficacy of new molecularly targeted drugs in the treatment of renal cell carcinoma (RCC), confirmed in clinical studies in relation to survival and prolongation of time to progression, has became a big chance for patients with metastatic renal cell cancer. Axitinib is a potent and selective recepto...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371698/ https://www.ncbi.nlm.nih.gov/pubmed/28373826 http://dx.doi.org/10.5114/wo.2015.51823 |
_version_ | 1782518473218326528 |
---|---|
author | Kuchar, Agata Hryciuk, Beata Stec, Rafał Mączewski, Michał Szczylik, Cezary |
author_facet | Kuchar, Agata Hryciuk, Beata Stec, Rafał Mączewski, Michał Szczylik, Cezary |
author_sort | Kuchar, Agata |
collection | PubMed |
description | Efficacy of new molecularly targeted drugs in the treatment of renal cell carcinoma (RCC), confirmed in clinical studies in relation to survival and prolongation of time to progression, has became a big chance for patients with metastatic renal cell cancer. Axitinib is a potent and selective receptor tyrosine kinase for vascular endothelial growth factor (VEGFR-1, -2, -3), platelet-derived growth factor β (PDGRF-β) and c-KIT. This is a case report of a 57-year old female patient with a history of left nephrectomy due to clear cell renal cell carcinoma. The patient had received three prior systemic treatments (interferon – sorafenib – everolimus). After consecutive progression the patient was qualified to 4(th) line therapy – axitinib at a dose of 5 mg twice daily. Partial response to treatment was achieved. After 6 months therapy was stopped due to the disease progression. The total time to progression was 37.5 months. The total survival time from the disease diagnosis was 45 months. Based on literature date and own experience we showed that sequential treatment RCC is associated with improved survival. In summary, axitinib may be an effective drug after failure of tyrosine-kinase inhibitor (TKI) therapy in previous lines of therapy. |
format | Online Article Text |
id | pubmed-5371698 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-53716982017-04-03 Axitinib in sequential therapy in metastatic renal cell carcinoma Kuchar, Agata Hryciuk, Beata Stec, Rafał Mączewski, Michał Szczylik, Cezary Contemp Oncol (Pozn) Case Report Efficacy of new molecularly targeted drugs in the treatment of renal cell carcinoma (RCC), confirmed in clinical studies in relation to survival and prolongation of time to progression, has became a big chance for patients with metastatic renal cell cancer. Axitinib is a potent and selective receptor tyrosine kinase for vascular endothelial growth factor (VEGFR-1, -2, -3), platelet-derived growth factor β (PDGRF-β) and c-KIT. This is a case report of a 57-year old female patient with a history of left nephrectomy due to clear cell renal cell carcinoma. The patient had received three prior systemic treatments (interferon – sorafenib – everolimus). After consecutive progression the patient was qualified to 4(th) line therapy – axitinib at a dose of 5 mg twice daily. Partial response to treatment was achieved. After 6 months therapy was stopped due to the disease progression. The total time to progression was 37.5 months. The total survival time from the disease diagnosis was 45 months. Based on literature date and own experience we showed that sequential treatment RCC is associated with improved survival. In summary, axitinib may be an effective drug after failure of tyrosine-kinase inhibitor (TKI) therapy in previous lines of therapy. Termedia Publishing House 2016-12-20 2016 /pmc/articles/PMC5371698/ /pubmed/28373826 http://dx.doi.org/10.5114/wo.2015.51823 Text en Copyright: © 2016 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Case Report Kuchar, Agata Hryciuk, Beata Stec, Rafał Mączewski, Michał Szczylik, Cezary Axitinib in sequential therapy in metastatic renal cell carcinoma |
title | Axitinib in sequential therapy in metastatic renal cell carcinoma |
title_full | Axitinib in sequential therapy in metastatic renal cell carcinoma |
title_fullStr | Axitinib in sequential therapy in metastatic renal cell carcinoma |
title_full_unstemmed | Axitinib in sequential therapy in metastatic renal cell carcinoma |
title_short | Axitinib in sequential therapy in metastatic renal cell carcinoma |
title_sort | axitinib in sequential therapy in metastatic renal cell carcinoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371698/ https://www.ncbi.nlm.nih.gov/pubmed/28373826 http://dx.doi.org/10.5114/wo.2015.51823 |
work_keys_str_mv | AT kucharagata axitinibinsequentialtherapyinmetastaticrenalcellcarcinoma AT hryciukbeata axitinibinsequentialtherapyinmetastaticrenalcellcarcinoma AT stecrafał axitinibinsequentialtherapyinmetastaticrenalcellcarcinoma AT maczewskimichał axitinibinsequentialtherapyinmetastaticrenalcellcarcinoma AT szczylikcezary axitinibinsequentialtherapyinmetastaticrenalcellcarcinoma |